Financial reports
NT 10-K
Notice of late annual filing
28 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
10 Mar 22
10-Q
2021 Q3
Quarterly report
4 Nov 21
10-Q
2021 Q2
Quarterly report
5 Aug 21
10-Q
2021 Q1
Quarterly report
6 May 21
10-K
2020 FY
Annual report
17 Mar 21
10-Q
2020 Q3
Quarterly report
19 Nov 20
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
28 Mar 23
8-K
Bankruptcy or Receivership
27 Mar 23
8-K
Codiak BioSciences Reports Third Quarter 2022 Financial Results and Third Quarter 2022 and Recent Highlights
3 Nov 22
8-K
Codiak Announces Proposed Public Offering of Common Stock and Warrants
13 Sep 22
8-K
Codiak BioSciences Announces Program Reprioritization and Corporate Restructuring
30 Aug 22
8-K
Codiak BioSciences Reports Second Quarter 2022 Financial Results and Second Quarter 2022 and Recent Highlights
4 Aug 22
8-K
Codiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials
30 Jun 22
8-K
Other Events
29 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
21 Jun 22
8-K
Codiak BioSciences Reports First Quarter 2022 Financial Results and Operational Progress
5 May 22
Registration and prospectus
25-NSE
Exchange delisting
2 May 23
424B5
Prospectus supplement for primary offering
13 Sep 22
424B5
Prospectus supplement for primary offering
12 Sep 22
S-8
Registration of securities for employees
10 Mar 22
S-3
Shelf registration
4 Nov 21
S-8
Registration of securities for employees
17 Mar 21
424B4
Prospectus supplement with pricing info
12 Feb 21
S-1MEF
Registration of additional securities for an S-1
11 Feb 21
S-1
IPO registration
9 Feb 21
DRS
Draft registration statement
29 Dec 20
Other
EFFECT
Notice of effectiveness
16 Nov 21
CORRESP
Correspondence with SEC
12 Nov 21
UPLOAD
Letter from SEC
12 Nov 21
EFFECT
Notice of effectiveness
12 Feb 21
CORRESP
Correspondence with SEC
9 Feb 21
CORRESP
Correspondence with SEC
9 Feb 21
UPLOAD
Letter from SEC
4 Jan 21
EFFECT
Notice of effectiveness
14 Oct 20
CERT
Certification of approval for exchange listing
13 Oct 20
CORRESP
Correspondence with SEC
8 Oct 20
Ownership
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
FMR LLC
10 Apr 23
4
Yalonda Howze
30 Mar 23
4
Sriram Sathyanarayanan
30 Mar 23
4
Konstantin Konstantinov
30 Mar 23
4
Linda Bain
30 Mar 23
4
Nicole Barna
30 Mar 23
4
DOUGLAS E WILLIAMS
30 Mar 23
SC 13G/A
Laurion Capital Management LP
3 Mar 23
4
Linda Bain
21 Feb 23